Newsroom

All News
  • All News
  • In the News
  • Press Releases
  • Publications
  • Events
HPR logo 2

Immunexpress – Near-Patient Diagnostic For Sepsis – SeptiCyte® RAPID

Dr. Rollie Carlson, CEO of Immunexpress discusses the development and commercialization plans for SeptiCyte® RAPID.  SeptiCyte® RAPID is a test that quantifies the immune response to infection and will provide actionable results in about one hour to guide physicians when making patient management decisions.
Immunexpress.com

Immunexpress Awarded BARDA Contract to Develop SeptiCyte® RAPID for COVID-19 Patient Triage

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, has been awarded a grant from the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS),...
applied-clinical-trials

Conquering Sepsis Clinical Trial Design

Designing and operating clinical trials for diagnosing sepsis can be a challenge, as the gold standard for sepsis detection offers a very low prediction rate due to the nature of how sepsis evolves in patients. FDA gold-standard septic blood cultures predict sepsis only 14% of the time, which makes it...
Express Healthcare

Biocartis Group partners with Immunexpress

For co-commercialisation agreement for SeptiCyte RAPID Test for use on Biocartis’ fully automated molecular diagnostics platform Idylla Biocartis Group recently announced the expansion of its partnership with Immunexpress with a co-commercialisation agreement for the SeptiCyte RAPID Test for use on Biocartis’ fully automated molecular diagnostics platform Idylla. The SeptiCyte RAPID...
genome web

Biocartis, Immunexpress Ink Co-Commercialization Agreement for Sepsis Test

Biocartis has expanded its current partnership with Seattle-based Immunexpress by launching a co-commercialization agreement for Immunexpress' SeptiCyte Rapid test on Biocartis' Idylla platform. As part of the expanded collaboration, Biocartis will lead commercialization in Europe as the exclusive distributor of the SeptiCyte Rapid test, while Immunexpress will lead commercialization of the test in the...
Immunexpress.com

Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte® RAPID

Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte® RAPID SeptiCyte® RAPID can swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis Commercialization of SeptiCyte® to triage COVID-19 patients will be the focus of Biocartis partnership in Europe   SEATTLE and BRISBANE,...
Sepsis-Alliance-Tagline_vert-clr

Innovation Webinar – “Challenges of Sepsis Diagnosis: Harnessing the Host Response”

Join us to learn about some of Immunexpress' recent innovations. This sponsored innovation webinar will address the shortcomings of past and current sepsis clinical criteria in accurately capturing patients with critical illness due to infection. The current status of microbiologic methods and single peptide biomarker will be described. A novel...
Immunexpress.com

Immunexpress Achieves ISO 13485:2016 & EN ISO 13485:2016 Quality Certification for Worldwide Commercialization of SeptiCyte® RAPID

Immunexpress, Pty Ltd & Inc., a molecular diagnostic company with the first FDA cleared host response assay for suspected sepsis patients, today announced that it has been successfully certified according to ISO 13485:2016 & EN ISO 13485:2016, the international standard for medical device quality management systems. The scope of the...
SeptiCyte-Logo-Horizontal-CMYK (002)

Tapas & Technology with a Live Demo of SeptiCyte® RAPID Test

Join the Immunexpress team for a cocktail reception of Tapas & Technology, during which you can enjoy Spanish Tapas with Rioja wine and watch a demonstration of SeptiCyte™ RAPID running and generating results on the BioCartis Idylla™ platform. There will also be two short presentations. Steven P. LaRosa, MD, Infectious...
Immunexpress.com

Immunexpress To Present at Biotech Showcase 2020 in San Francisco

Immunexpress, Inc., a medical diagnostic company focused on improving outcomes for suspected sepsis patients, today announced that its Chief Executive Officer, Rolland Carlson, Ph.D., will present at Biotech Showcase 2020, to be held January 13-15 at the Hilton San Francisco Union Square. Dr. Carlson will present an overview of the...
Immunexpress.com

Immunexpress Announces Grant of U.S. Patent Covering the Differentiation of Gram-Positive and Gram-Negative Sepsis-Causing Bacteria

The patent includes classification techniques using single nucleotide polymorphisms (SNPs) in the ribosomal DNA of sepsis organisms Identification and classification of sepsis organisms leads to improved antibiotic decision-making SEATTLE, Nov. 21, 2019 – Immunexpress, Inc. today announced the U.S. Patent and Trademark Office (USPTO) has granted Patent No. U.S. 10,364,474...
Immunexpress.com

Immunexpress Announces Closing of Private Funding Round

Immunexpress Announces Closing of Private Funding Round Funding will support the development of SeptiCyte™ RAPID through FDA 510(k) Clearance CE Marking of SeptiCyte™ RAPID anticipated in 1Q2020, FDA Clearance anticipated mid-2020 SEATTLE, Oct. 3, 2019 /PRNewswire/ -- Immunexpress, Inc., a medical diagnostic company focused on improving outcomes for suspected sepsis patients, today announced...

If you are a member of the media, please contact:

Maggie Beller
Russo Partners
(646) 942-5631
maggie.beller@russopartnersllc.com